Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Dec 04, 2020 3:24pm
146 Views
Post# 32039208

RE:RE:RE:Warrants

RE:RE:RE:WarrantsExactly my point.  The warrants and shares will all move in tandem so the value is equivalent so investors dont move between vehicles.  If you purchase warrants be prepared to hold for dollars and you may have to pay to exercise in the event of buyout or adjustment from the company.  If you hold warrants in a TFSA, or RSP you may not be able to contribute additional funds in order to exercise so make sure you have the ability to exercise your shares.  

In general, there is added risk, less liquidity, non voting and chance of the requirement to exercise prior to expire, adjustment or buyout so understand what you are buying.

If you are not familiar with warrants stick to shares.



Str8Shuter wrote: I guess I was wrong yesterday about the newly issued warrants not being tradable.  Can't understand how that excerpt from the aforementioned Short Form Prospectus could be interpreted any other way, but perhaps they quite literally meant that "currently" there was no market for the new warrants even though there was a plan to list them on the TSX the very next day after the offering closed.

Anyway, each is a 3-year warrant to buy a share for $1.10.  There were only 9,243,700 Units sold, including half warrants.  So, around 4.62MM new warrants with ticker symbol SZLS.WS were issued, if I understand correctly.  In contrast, there were 66.2MM warrants issued in the previous public offering (SZLS.WT), so the new ones will be considerably less liquid which implies much higher volatility (i.e. risk).

With the WS trading at $0.15 and WT at $0.065 today, it looks to me like they offer similar value, but since WT has much higher liquidity, it seems to offer a better risk/reward opportunity, IMHO.

Would be interested to know if anyone sees things differently, or has any other comments.


Str8Shuter wrote: Good question.  StageZERO has issued warrants on a number of occasions in the past, with various exercise prices and expiry dates.  None of them had ever been publicly tradeable until June 29, 2020, when they closed a public offering with Echelon and Clarus that included the publicly tradeable warrants we all know fondly as SZLS.WT.

As far as I can tell, the soon-to-be issued warrants (including non-transferable broker warrants) will NOT be publicly tradeable.  So, I don't think that there should be any effect on SZLS.WT whatsoever.

Following is a key excerpt from the amended short form prospectus dated Oct. 19, 2020:

"There is currently no market through which the Warrants may be sold and purchasers may not be able to resell the Warrants purchased under this Prospectus. This may affect the pricing of the Warrants in the secondary market, the transparency and availability of trading prices, the liquidity of the securities, and the extent of issuer regulation. See “Risk Factors”.  "


I'm not a lawyer, but that's my two cents on matter.  GLTA!


brad129 wrote: To those more educated on the warrant side of things are the last round of warrants dropping in value because the new ones will be available for pennies to start with? If they have a strike price of $1.10 wouldn't they be the better value( depending what people can purchase them for)

 




<< Previous
Bullboard Posts
Next >>